Adagene Inc. (ADAG)
NASDAQ: ADAG · Real-Time Price · USD
2.050
+0.050 (2.50%)
Dec 20, 2024, 4:00 PM EST - Market closed
Adagene Employees
Adagene had 174 employees as of December 31, 2023. The number of employees decreased by 74 or -29.84% compared to the previous year.
Employees
174
Change (1Y)
-74
Growth (1Y)
-29.84%
Revenue / Employee
$4,688
Profits / Employee
-$183,042
Market Cap
90.76M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 174 | -74 | -29.84% |
| Dec 31, 2022 | 248 | -11 | -4.25% |
| Dec 31, 2021 | 259 | 61 | 30.81% |
| Dec 31, 2020 | 198 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| bluebird bio | 375 |
| Century Therapeutics | 165 |
| OptimizeRx | 136 |
| LENSAR | 130 |
| Fractyl Health | 102 |
| HilleVax | 90 |
| Zentek | 24 |
| Nuvectis Pharma | 13 |
ADAG News
- 6 weeks ago - Adagene Presents Two Posters with New Insights on Increased Therapeutic Index for Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) and Data Reinforcing Clinical Safety and Efficacy for ADG126 as Monotherapy and in Combination with Anti-PD-1 Therapy at Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting - GlobeNewsWire
- 2 months ago - Adagene Announces Upcoming Poster Presentations on Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) at Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting - GlobeNewsWire
- 3 months ago - Adagene Presents Results at ESMO Congress that Show Best-in-Class Therapeutic Potential for Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) in Combination with KEYTRUDA® (Pembrolizumab) in Advanced/Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC) - GlobeNewsWire
- 5 months ago - Adagene Announces Poster Presentation on Masked Anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in MSS CRC at Upcoming European Society for Medical Oncology (ESMO) Congress in September - GlobeNewsWire
- 7 months ago - Adagene to Present at Investor Conferences in June - GlobeNewsWire
- 9 months ago - Adagene Reports Full Year 2023 Financial Results and Provides Corporate Update - GlobeNewsWire
- 10 months ago - Adagene Appoints Heinz-Josef Lenz, M.D., FACP to Scientific and Strategic Advisory Board - GlobeNewsWire
- 10 months ago - Adagene to Present at the Leerink Partners Global Biopharma Conference 2024 - GlobeNewsWire